| Cat. No. |
Product Name |
Information |
| PC-25402 |
TP-1287
CDK9 inhibitor
|
TP-1287 is a prodrug of Alvocidib (Flavopiridol, HMR-1275), is an orally active CDK9 inhibitor. |
| PC-25401 |
BRD6866
TFE3 inhibitor, CDK9 inhibitor
|
BRD6866 is a small molecule inhibitor of TFE3 transcription factor fusion activity with IC50 of 342 nM, shows dose-dependent chromatin trapping of TFE3, potent pan-CDK inhibitor across all families of CDKs, including both cell-cycle and transcriptional CDK9, suppresses tRCC cell growth. |
| PC-25380 |
LC-K2CAin-1
CDK2–Cyclin A2 inhibitor
|
LC-K2CAin-1 is a potent, highly selective CDK2-Cyclin A2 protein-protein interaction (PPI) inhibitor with IC50 of 59.57 nM in HTRF assays. |
| PC-25379 |
LC-K2CAin-3
CDK2–Cyclin A2 inhibitor
|
LC-K2CAin-3 is a potent, highly selective CDK2-Cyclin A2 protein-protein interaction (PPI) inhibitor with IC50 of 32.1 nM in HTRF assays. |
| PC-25359 |
CIRc-028
Cyclin A/B RxL inhibitor
|
CIRc-028 is a potent, in vivo-active, orally bioavailable dual cyclin A/B RxL inhibitor, inhibits cyclin A/B-RxL interactions and induces apoptosis in cancer cells with high E2F activity, induced spindle assembly checkpoint (SAC) activation and apoptosis in vivo. |
| PC-25129 |
YX0798
CDK9 inhibitor
|
YX0798 is a potent, selective and oral bioavailable CDK9 inhibitor with binding Kd of 0.28 nM, 16-50-fold more selective for CDK9 than CDK7, CDK3, or CDK4. |
| PC-25121 |
BEBT-209
CDK4 inhibitor
|
BEBT-209 is a potent, selective and orally active CDK4 inhibitor, 6-fold selective over CDK6. |
| PC-24960 |
Mocaciclib
CDK7 inhibitor
|
Mocaciclib (Q901) is a highly selective and potent CDK7 inhibitor, forms a covalent bond with C312 of the CDK7 C-terminal domain. |
| PC-24695 |
FCN-437c
CDK4/6 inhibitor
|
FCN-437c (FCN-437) is a potent, selective and orally active inhibitor of CDK4/6, shows selective inhibitory activities against CDK4/6 over other CDKs. |
| PC-24595 |
MRT-9643
CDK2 degrader
|
MRT-9643 (MRT9643) is a potent, selective and orally active CDK2-directed molecular glue degrader, induces CDK2-dependent cancer cell growth inhibition. |
| PC-24494 |
Y041-2712
CDK8 inhibitor
|
Y041-2712 is a potent, selective CDK8 inhibitor with IC50 value of 398.8 nM, inhibits TGF-β/Smad signaling pathway and the expression of EMT proteins. |
| PC-24482 |
LA-CB1
CDK4/6 degrader
|
LA-CB1 is a novel Abemaciclib derivative that induces CDK4/6 degradation through the ubiquitin-proteasome pathway, exerts robust anti-proliferative effects across a wide spectrum of cancer cell lines (A498 cell, IC50=0.21 uM). |
